Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Dendritic cell-based immunotherapy.

Publication ,  Journal Article
Osada, T; Clay, TM; Woo, CY; Morse, MA; Lyerly, HK
Published in: Int Rev Immunol
2006

Dendritic cells (DCs) play a crucial role in the induction of antigen-specific T-cell responses, and therefore their use for the active immunotherapy of malignancies has been studied with considerable interest. More than a decade has passed since the publication of the first clinical data of DC-based vaccines, and through this and subsequent studies, a number of important developmental insights have been gleaned. These include the ideal source and type of DCs, the discovery of novel antigens and methods of loading DCs, the role of DC maturation, and the most efficient route of immunization. The generation of immune responses against tumor antigens after DC immunization has been demonstrated, and favorable clinical responses have been reported in some patients; however, it is difficult to pool the results as a whole, and thus the body of data remains inconclusive, in part because of varying DC preparation and vaccination protocols, the use of different forms of antigens, and, most importantly, a lack of rigorous criteria for defining clinical responses. As such, the standardization of clinical and immunologic criteria utilized, as well as DC preparations employed, will allow for the comparison of results across multiple clinical studies and is required in order for future trials to measure the true value and role of this treatment modality. In addition, issues regarding the optimal dose and clinical setting for the application of DC vaccines remain to be resolved, and recent clinical studies have been designed to begin to address these questions.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int Rev Immunol

DOI

ISSN

0883-0185

Publication Date

2006

Volume

25

Issue

5-6

Start / End Page

377 / 413

Location

England

Related Subject Headings

  • Neoplasms
  • Immunotherapy
  • Immunology
  • Humans
  • Dendritic Cells
  • Clinical Trials as Topic
  • Cancer Vaccines
  • Antigens, Neoplasm
  • Antigen Presentation
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Osada, T., Clay, T. M., Woo, C. Y., Morse, M. A., & Lyerly, H. K. (2006). Dendritic cell-based immunotherapy. Int Rev Immunol, 25(5–6), 377–413. https://doi.org/10.1080/08830180600992456
Osada, Takuya, Timothy M. Clay, Christopher Y. Woo, Michael A. Morse, and H Kim Lyerly. “Dendritic cell-based immunotherapy.Int Rev Immunol 25, no. 5–6 (2006): 377–413. https://doi.org/10.1080/08830180600992456.
Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK. Dendritic cell-based immunotherapy. Int Rev Immunol. 2006;25(5–6):377–413.
Osada, Takuya, et al. “Dendritic cell-based immunotherapy.Int Rev Immunol, vol. 25, no. 5–6, 2006, pp. 377–413. Pubmed, doi:10.1080/08830180600992456.
Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK. Dendritic cell-based immunotherapy. Int Rev Immunol. 2006;25(5–6):377–413.
Journal cover image

Published In

Int Rev Immunol

DOI

ISSN

0883-0185

Publication Date

2006

Volume

25

Issue

5-6

Start / End Page

377 / 413

Location

England

Related Subject Headings

  • Neoplasms
  • Immunotherapy
  • Immunology
  • Humans
  • Dendritic Cells
  • Clinical Trials as Topic
  • Cancer Vaccines
  • Antigens, Neoplasm
  • Antigen Presentation
  • 3204 Immunology